Mucus hypersecretion in asthma: Intracellular signalling pathways as targets for pharmacotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 1, 2010, Pages 67-76

  Lai, Hon Yee ^a   Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway; Epidermal growth factor; Goblet cell; IL 13; Mucin

Indexed keywords

ADALIMUMAB; BATIMASTAT; CALCIUM CHANNEL; CYCLOOXYGENASE 2; ELASTASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETANERCEPT; GEFITINIB; HEPATOCYTE NUCLEAR FACTOR 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 9; SORAFENIB; SURAMIN; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ASTHMA; CELL HYPERPLASIA; DISEASE SEVERITY; GENE EXPRESSION; GOBLET CELL; HUMAN; INFLAMMATION; MUCUS SECRETION; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; UPREGULATION;

ANIMALS; ASTHMA; DRUG DELIVERY SYSTEMS; DRUG THERAPY; GOBLET CELLS; HUMANS; HYPERPLASIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCUS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 76149124216     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328334643a     Document Type: Review

References (76)

1. Braman SS. The global burden of asthma. Chest 2006; 130:4S-12S.
2. Matthew M, Denise F, Shaun H, Richard B. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59:469-478.
3. Godard P, Chanez P, Siraudin L, et al.. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19:61-67.
4. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 2004; 4:241-250.
5. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007; 52:1176-1193; discussion 1193-11177
6. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007; 52:1134-1146; discussion 1146-1149.
7. Del Donno M, Bittesnich D, Chetta A, et al.. The effect of inflammation on mucociliary clearance in asthma: an overview. Chest 2000; 118:1142-1149.
8. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109:571-577.
9. Davies JR, Herrmann A, Russell W, et al.. Respiratory tract mucins: structure and expression patterns. Novartis Found Symp 2002; 248:76-88; discussion 88-93, 277-282.
10. Sheehan JK, Thornton DJ, Somerville M, Carlstedt I. Mucin structure. The structure and heterogeneity of respiratory mucus glycoproteins. Am Rev Respir Dis 1991; 144:S4-S9.
11. Williams OW, Sharafkhaneh A, Kim V, et al.. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006; 34:527-536.
12. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006; 86:245-278.
13. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009; 135:505-512.
14. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008; 70:459-486.
15. Ordonez CL, Khashayar R, Wong HH, et al.. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001; 163:517-523.
16. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164:S28-S38.
17. Jeffery PK. Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Experiment Allergy 1999; 29:14-26.
18. Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulmon Med 2008; 14:31-38.
19. Evans CM, Kim K, Tuvim MJ, Dickey BF. Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulmon Med 2009; 15:4-11.
20. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:176-183.
21. Fahy JV. Goblet cell and mucin gene abnormalities in asthma. Chest 2002; 122:320S-326S.
22. Aikawa T, Shimura S, Sasaki H, et al.. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101:916-921.
23. Hackett T, Shaheen F, Johnson A, et al.. Characterization of side population cells from human airway epithelium. Stem Cells 2008; 26:2576-2585.
24. Rogers DF, Evans TW. Plasma exudation and oedema in asthma. Br Med Bull 1992; 48:120-134.
25. Bhaskar KR, O'Sullivan DD, Coles SJ, et al.. Characterization of airway mucus from a fatal case of status asthmaticus. Pediatr Pulmonol 1988; 5:176-182.
26. Sheehan JK, Richardson PS, Fung DC, et al.. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995; 13:748-756.
27. List SJ, Findlay BP, Forstner GG, Forstner JF. Enhancement of the viscosity of mucin by serum albumin. Biochem J 1978; 175:565-571.
28. Shimura S, Andoh Y, Haraguchi M, Shirato K. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J 1996; 9:1395-1401.
29. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112:819-827; quiz 828.
30. Lora JM, Zhang DM, Liao SM, et al.. Tumor necrosis factor-a triggers mucus production in airway epithelium through an IkB kinase b-dependent mechanism. J Biol Chem 2005; 280:36510-36517.
31. Song KS, Lee W-J, Chung KC, et al.. Interleukin-1b and tumor necrosis factor-a induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem 2003; 278:23243-23250.
32. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003; 285:L730-L739.
33. Vermeer PD, Harson R, Einwalter LA, et al.. Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am J Respir Cell Mol Biol 2003; 28:286-295.
34. Whittaker L, Niu N, Temann UA, et al.. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002; 27:593-602.
35. Steenwinckel V, Louahed J, Orabona C, et al.. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178:3244-3251.
36. Kuperman DA, Huang X, Koth LL, et al.. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002; 8:885-889.
37. Wan H, Kaestner KH, Ang S-L, et al.. Foxa2 regulates alveolarization and goblet cell hyperplasia. Development 2004; 131:953-964.
38. Chu HW, Balzar S, Seedorf GJ, et al.. Transforming growth factor-b2 induces bronchial epithelial mucin expression in asthma. Am J Pathol 2004; 165: 1097-1106.
39. Nakao I, Kanaji S, Ohta S, et al.. Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. J Immunol 2008; 180:6262-6269.
40. Toda M, Tulic MK, Levitt RC, Hamid Q. A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002; 109:246-250.
41. Shim JJ, Dabbagh K, Ueki IF, et al.. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol 2001; 280:L134-L140.
42. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000; 64:821-846.
43. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11:372-377.
44. Hsu H, Shu H-B, Pan M-G, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84:299-308.
45. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IB kinase activity through IKK subunit phosphorylation. Science 1999; 284:309-313.
46. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKg) upon receptor stimulation. Immunity 2000; 12:301-311.
47. Li D, Gallup M, Fan N, et al.. Cloning of the amino-terminal and 5'-flanking region of the human MUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts. J Biol Chem 1998; 273:6812-6820.
48. Desmet C, Gosset P, Pajak B, et al.. Selective blockade of NF-kB activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 2004; 173:5766-5775.
49. Sousa AR, Lane SJ, Nakhosteen JA, et al.. Expression of interleukin-1b and interleukin-1 receptor antagonist on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996; 154:1061-1066.
50. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulmon Pharmacol Therapeut 2002; 15:35-50.
51. Gray T, Nettesheim P, Loftin C, et al.. Interleukin-1b-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol 2004; 66:337-346.
52. Kim Y-D, Kwon E-J, Park D-W, et al.. Interleukin-1b induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 Cells. Mol Pharmacol 2002; 62:1112-1118.
53. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006; 119:229-240.
54. Gray T, Coakley R, Hirsh A, et al.. Regulation of MUC5AC mucin secretion and airway surface liquid metabolism by IL-1b in human bronchial epithelia. Am J Physiol Lung Cell Mol Physiol 2004; 286:L320-L330.
55. Takeyama K, Fahy JV, Nadel JA. Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 2001; 163:511-516.
56. Hewson CA, Edbrooke MR, Johnston SL. PMA induces the MUC5AC respiratory mucin in human bronchial epithelial cells, via PKC, EGF/TGF-a, Ras/Raf, MEK, ERK and Sp1-dependent mechanisms. J Molec Biol 2004; 344:683-695.
57. Zhen G, Park SW, Nguyenvu LT, et al.. IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production. Am J Respir Cell Mol Biol 2007; 36:244-253.
58. Nadel JA, Takeyama K, Dabbagh K, et al.. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999; 96:3081-3086.
59. Shao MXG, Nadel JA. Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-a-converting enzyme. J Immunol 2005; 175:4009-4016.
60. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol 2002; 283:L531-L540. (Pubitemid 34941001)
61. Karras JG, Crosby JR, Guha M, et al.. Anti-inflammatory activity of inhaled IL-4 receptor-a antisense oligonucleotide in mice. Am J Respir CellMol Biol 2007; 36:276-285.
62. Henderson WR Jr, Chi EY, Maliszewski CR. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000; 164:1086-1095.
63. Blanchard C, Mishra A, Saito-Akei H, et al.. Inhibition of human interleukin-13- induced respiratory and oesophageal inflammation by antihuman-interleukin- antibody (CAT-354). Clin Experiment Allergy 2005; 35:1096-1103.
64. Kasaian MT, Donaldson DD, Tchistiakova L, et al.. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007; 36:368-376.
65. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38:116-125.
66. Mora AL, LaVoy J, McKean M, et al.. Prevention of NF-kB activation in vivo by a cell-permeable NF-kB inhibitor peptide. Am J Physiol Lung Cell Mol Physiol 2005; 289:L536-L544.
67. Kinyanjui MW, Fixman ED. Cell-penetrating peptides and proteins: new inhibitors of allergic airways disease. Can J Physiol Pharmacol 2008; 86:1-7.
68. McCusker CT, Wang Y, Shan J, et al.. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J Immunol 2007; 179:2556-2564.
69. Brightling C, Berry M, Amrani Y. Targeting TNF-a: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121:5-10.
70. Robichaud A, Tuck SA, Kargman S, et al.. Gob-5 is not essential for mucus overproduction in preclinical murine models of allergic asthma. Am J Respir Cell Mol Biol 2005; 33:303-314.
71. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004; 59:992-996.
72. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 (Suppl 1):15-23; discussion 41-112
73. Wilhelm SM, Adnane L, Newell P, et al.. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molec Cancer Therapeut 2008; 7:3129-3140.
74. Puddicombe S, Polosa R, Richter A, et al.. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14:1362-1374.
75. Stevens P, Kicic A, Sutanto E, et al.. Dysregulated repair in asthmatic paediatric airway epithelial cells: the role of plasminogen activator inhibitor- 1. Clin Exp Allergy 2008; 38:1901-1910.
76. Hackett T, Warner S, Stefanowicz D, et al.. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-b1. Am J Respir Crit Care Med 2009; 180:122-133.